Tivic Health Systems, INC 8-K filings

Tivic Health Systems, Inc. has amended its exclusive license agreement with Statera Biopharma, Inc., revising payment terms to allow for cash or stock and increasing the lien held by Avenue Venture Opportunities Fund, L.P. to up to $5.6 million.

Tivic Health Systems, Inc. announced the appointment of Lisa Wolf as permanent Chief Financial Officer, the transition of its Chief Scientific Officer to a consultant role, and stockholder approval of an amended equity incentive plan and several significant stock issuances.

Tivic Health Systems, Inc. has entered into an Amended and Restated Exclusive License Agreement with Statera Biopharma, Inc., modifying payment terms for the exclusive worldwide license to Statera's proprietary TLR5 agonist program, including direct payments to Avenue Capital to extinguish a lien.

Tivic Health Systems, Inc. announced the completion of its Optimization Study for its non-invasive vagus nerve stimulation device, with breakthrough findings expected to be reported later this year and applied to an upcoming Phase I clinical trial.

Tivic Health Systems unveils a reinvented strategy focusing on immunotherapeutics and non-invasive vagus nerve stimulation, targeting a $183 billion market.

Tivic Health Systems sets the date for its virtual 2025 Annual Meeting of Stockholders and outlines revised deadlines for shareholder proposals and director nominations.

Tivic Health Systems, Inc. announced its Q1 2025 financial results, highlighting a strategic shift towards immunotherapeutics and bioelectronic medicine.

Tivic Health Systems partners with Scorpius BioManufacturing to validate the manufacturing process for Entolimod, a treatment for Acute Radiation Syndrome, in preparation for FDA submission.

Tivic Health Systems enters into a securities purchase agreement for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants.

Tivic Health reports positive discussions with the White House and FDA regarding its TLR5 and vagus nerve stimulation programs for potential military and defense applications.

Tivic Health Systems announces the potential sale of up to $1,767,913 in common stock through Maxim Group LLC under an existing equity distribution agreement.

Tivic Health Systems, Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid requirements, allowing its common stock to continue trading on the Nasdaq Capital Market.

Tivic Health Systems exercises its option to acquire the exclusive worldwide license for the Neutropenia indication of Entolimod and issues shares to Statera Biopharma and Avenue Venture Opportunities Fund.

Tivic Health Systems, Inc. announces a $25M equity purchase agreement, year-end 2024 financial results, and highlights its strategic transformation into a diversified therapeutics company.

Tivic Health Systems, Inc. announced new data demonstrating that personalized non-invasive vagus nerve stimulation (ncVNS) optimizes the impact on autonomic nervous system activity, supporting the development of personalized neuromodulation devices.

Tivic Health Systems, Inc. will implement a 1-for-17 reverse stock split effective March 7, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Michael Handley, former CEO of Statera Biopharma, joins Tivic Health to lead the newly formed Tivic Biopharma division and serve as Chief Operating Officer.

Tivic Health Systems acquires exclusive worldwide license rights from Statera Biopharma to Entolimod, a late-stage Toll-like Receptor 5 (TLR5) agonist, for the treatment of acute radiation syndrome (ARS), diversifying its therapeutics pipeline.

Tivic Health Systems' stockholders approved a proposal granting the board discretionary authority to implement a reverse stock split and to adjourn the special meeting if needed.

Tivic Health Systems, Inc. has received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement and is requesting a hearing to appeal the decision.

Tivic Health is shifting its focus to vagus nerve stimulation (VNS) while reporting significant improvements in gross margins and a reduction in net operating losses.

Tivic Health announced its third quarter 2024 financial results, showcasing progress in supply chain improvements and the development of its vagus nerve stimulation technology.

Tivic Health has received approval from The Feinstein Institutes Institutional Review Board to begin the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (ncVNS) technology.

Tivic Health has partnered with Fletcher Spaght to develop a commercial strategy for its non-invasive cervical vagus nerve stimulation technology.

Tivic Health Systems has entered into an agreement to sell up to $10 million of its common stock and appointed a new interim CFO, effective October 1, 2024.

Tivic Health announced its second quarter 2024 financial results, showcasing progress in vagus nerve stimulation research and cost reduction efforts.

Tivic Health Systems has amended and restated its 2021 Equity Incentive Plan, increasing the number of shares authorized for issuance and removing certain limitations on awards.

Tivic Health Systems terminated its fulfillment services agreement with ALOM Technologies to reduce costs and transitioned to new logistics and in-house assembly.

Tivic Health Systems has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement due to its stock price falling below $1 for 33 consecutive days.

Tivic Health Systems has appointed Christina Valauri to its board of directors, effective July 1, 2024, while Karen Drexler will resign from the board effective September 30, 2024.